342
Participants
Start Date
March 31, 2011
Primary Completion Date
December 31, 2016
Study Completion Date
March 31, 2017
HMG-CoA Reductase Inhibitor
"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
Probucol
"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
Cilostazol
"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
Dong-A Medical Center, Seogu
Samsung Medical Center, Seoul
Seoul National University Bundang Hospital, Seongnam-si
Seoul National University Hospital, Seoul
Boramae Medical Center, Seoul
Collaborators (1)
Korea Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Seoul National University Hospital
OTHER